Vitamin C attenuates hypochlorite-mediated loss of paraoxonase-1 activity from human plasma

Nutrition Research

Volumn 29, Issue 2, 2009, Pages 114-122

  Kunes, Jacob P ^a   Cordero Koning, Katie S ^b   Lee, Lionel H ^b   Lynch, Sean M ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Antioxidants; Ascorbic acid; Cardiovascular diseases; Human; Hypochlorous acid; Lipoproteins, HDL; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; ASCORBIC ACID; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN; HYPOCHLORITE; LOW DENSITY LIPOPROTEIN; LYSINE; PHOSPHOTRIESTERASE; TOSYLCHLORAMIDE SODIUM;

ARTICLE; ATTENUATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; IC 50; INCUBATION TIME; ISOLATION PROCEDURE; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ASCORBIC ACID; CARBOXYLIC ESTER HYDROLASES; CARDIOVASCULAR DISEASES; HUMANS; HYPOCHLOROUS ACID; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; PHOSPHORIC TRIESTER HYDROLASES;

EID: 61749084202     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2009.01.003     Document Type: Article

References (59)

1. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
2. Francis G.A. High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. Biochim Biophys Acta 1483 (2000) 217-235
3. Klebanoff S.J. Myeloperoxidase: friend and foe. J Leukoc Biol 77 (2005) 598-625
4. Zheng L., Nukuna B., Brennan M.L., Sun M., Goormastic M., Settle M., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114 (2004) 529-541
5. Young C.E., Karas R.H., and Kuvin J.T. High-density lipoprotein cholesterol and coronary heart disease. Cardiol Rev 12 (2004) 107-119
6. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 473-480
7. Khersonsky O., and Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44 (2005) 6371-6382
8. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., Tawfik D.S., et al. The catalytic histidine dyad of HDL-associated serum paraoxonase 1 (PON1) is essential for PON1-mediated inhibition of LDL oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 281 (2006) 7657-7665
9. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., and La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46 (2005) 1239-1247
10. Troughton J.A., Woodside J.V., Yarnell J.W.G., Arveiler D., Amouyel P., Ferrieres J., et al. Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: the PRIME study. Atherosclerosis 197 (2008) 556-563
11. Frei B., England L., and Ames B.N. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 86 (1989) 6377-6381
12. Hillstrom R.J., Yacapin-Ammons A.K., and Lynch S.M. Vitamin C inhibits lipid oxidation in human HDL. J Nutr 133 (2003) 3047-3051
13. Calla M.S., and Lynch S.M. Vitamin C preserves the cardio-protective paraoxonase activity of high-density lipoprotein during oxidant stress. Arch Biochem Biophys 452 (2006) 129-137
14. Malle E., Marsche G., Panzenboeck U., and Sattler W. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys 445 (2006) 245-255
15. Bell C., Jones P.P., and Seals D.R. Oxidative stress does not modulate metabolic rate or skeletal muscle sympathetic activity with primary aging in adult humans. J Clin Endocrinol Metab 88 (2003) 4950-4954
16. Goldenberg H. Vitamin C: from popular food supplement to specific drug. Forum Nutr 56 (2003) 42-45
17. McGregor G.P., and Biesalski H.K. Rationale and impact of vitamin C in clinical nutrition. Curr Opin Clin Nutr Metab Care 9 (2006) 697-703
18. Chung B.H., Segrest J.P., Ray M.J., Brunzell J.D., Hokanson J.E., Krauss R.M., et al. Single vertical spin density gradient ultracentrifugation. Methods Enzymol 128 (1986) 181-209
19. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83 (1977) 346-356
20. Lowry O., Rosebrough N., Farr A., and Randall R. Protein estimation with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
21. Panzenboeck U., Raitmayer S., Reicher H., Lindner H., Glatter O., Malle E., et al. Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins. J Biol Chem 272 (1997) 29711-29720
22. Bergt C., Reicher H., Malle E., and Sattler W. Hypochlorite modification of high density lipoprotein: effects on cholesterol efflux from J774 macrophages. FEBS Lett 452 (1999) 295-300
23. Carr A.C., Tijerina T., and Frei B. Vitamin C protects against and reverses specific hypochlorous acid- and chloramine-dependent modifications of low-density lipoprotein. Biochem J 346 (2000) 491-499
24. Marsche G., Furtmuller P.G., Obinger C., Sattler W., and Malle E. Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro. Cardiovasc Res 79 (2008) 187-194
25. Bohlen P., Stein S., Dairman W., and Udenfriend S. Fluorometric assay of proteins in the nanogram range. Arch Biochem Biophys 155 (1973) 213-220
26. Kettle A.J., and Winterbourn C.C. Assays for the chlorination activity of myeloperoxidase. Methods Enzymol 233 (1994) 502-512
27. Esterbauer H., Dieber-Rotheneder M., Waeg M., Striegl G., and Jurgens G. Biochemical, structural, and functional properties of oxidized low- density lipoprotein. Chem Res Toxicol 3 (1990) 77-92
28. Mackness B., Mackness M.I., Arrol S., Turkie W., and Durrington P.N. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122 (1997) 265-268
29. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18 (1998) 1617-1624
30. Khersonsky O., and Tawfik D.S. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. Chembiochem 7 (2006) 49-53
31. James R.W. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 44 (2006) 1052-1059
32. Jerlich A., Hammel M., Nigon F., Chapman M.J., and Schaur R.J. Kinetics of tryptophan oxidation in plasma lipoproteins by myeloperoxidase-generated HOCl. Eur J Biochem 267 (2000) 4137-4143
33. Nguyen S.D., and Sok D.E. Oxidative inactivation of paraoxonase 1, an antioxidant protein, and its effect on antioxidant action. Free Radic Res 37 (2003) 1319-1330
34. Sutherland W.H., de Jong S.A., and Walker R.J. Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study. Nephrol Dial Transplant 19 (2004) 75-82
35. Deakin S., Moren X., and James R.W. HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity. Arterioscler Thromb Vasc Biol 27 (2007) 1146-1152
36. Gugliucci A. Hypochlorous acid is a potent inactivator of human plasminogen at concentrations secreted by activated granulocytes. Clin Chem Lab Med 46 (2008) 1403-1409
37. Dabbagh A.J., and Frei B. Human suction blister interstitial fluid prevents metal ion-dependent oxidation of low density lipoprotein by macrophages and in cell-free systems. J Clin Invest 96 (1995) 1958-1966
38. Roche M., Rondeau P., Singh N.R., Tarnus E., and Bourdon E. The antioxidant properties of serum albumin. FEBS Lett 582 (2008) 1783-1787
39. Hu M.L., Louie S., Cross C.E., Motchnik P., and Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 121 (1993) 257-262
40. Carr A.C., Hawkins C.L., Thomas S.R., Stocker R., and Frei B. Relative reactivities of N-chloramines and hypochlorous acid with human plasma constituents. Free Radic Biol Med 30 (2001) 526-536
41. Vermeer B.J., Reman F.C., and van Gent C.M. The determination of lipids and proteins in suction blister fluid. J Invest Dermatol 73 (1979) 303-305
42. Vessby B., Gustafson S., Chapman M.J., Hellsing K., and Lithell H. Lipoprotein composition of human suction-blister interstitial fluid. J Lipid Res 28 (1987) 629-641
43. Mackness M.I., Mackness B., Arrol S., Wood G., Bhatnagar D., and Durrington P.N. Presence of paraoxonase in human interstitial fluid. FEBS Lett 416 (1997) 377-380
44. Parini P., Johansson L., Broijersen A., Angelin B., and Rudling M. Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest 36 (2006) 98-104
45. Foote C.S., Goyne T.E., and Lehrer R.I. Assessment of chlorination by human neutrophils. Nature 301 (1983) 715-716
46. Weiss S.J., Klein R., Slivka A., and Wei M. Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation. J Clin Invest 70 (1982) 598-607
47. Coller B.S. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?. Arterioscler Thromb Vasc Biol 25 (2005) 658-670
48. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299 (2008) 1265-1276
49. Yildiz A., Gur M., Demirbag R., Yilmaz R., Akyol S., Aslan M., et al. Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients. Clin Biochem 41 (2008) 779-784
50. Yildiz A., Gur M., Yilmaz R., Demirbag R., Polat M., Selek S., et al. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 197 (2008) 257-263
51. Soran N., Altindag O., Cakir H., Celik H., Demirkol A., and Aksoy N. Assessment of paraoxonase activities in patients with knee osteoarthritis. Redox Rep 13 (2008) 194-198
52. Ferretti G., Bacchetti T., Masciangelo S., and Pallotta G. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 41 (2008) 381-386
53. Padayatty S.J., Sun H., Wang Y., Riordan H.D., Hewitt S.M., Katz A., et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (2004) 533-537
54. Folkes L.K., Candeias L.P., and Wardman P. Kinetics and mechanisms of hypochlorous acid reactions. Arch Biochem Biophys 323 (1995) 120-126
55. Carr A.C., and Frei B. Human neutrophils oxidize low-density lipoprotein by a hypochlorous acid-dependent mechanism: the role of vitamin C. Biol Chem 383 (2002) 627-636
56. Hawkins C.L., and Davies M.J. Hypochlorite-induced damage to proteins: formation of nitrogen-centred radicals from lysine residues and their role in protein fragmentation. Biochem J 332 (1998) 617-625
57. Hawkins C.L., and Davies M.J. Hypochlorite-induced oxidation of proteins in plasma: formation of chloramines and nitrogen-centred radicals and their role in protein fragmentation. Biochem J 340 (1999) 539-548
58. Carr A.C., McCall M.R., and Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 20 (2000) 1716-1723
59. Carr A.C. Hypochlorous acid-modified low-density lipoprotein inactivates the lysosomal protease cathepsin B: protection by ascorbic and lipoic acids. Redox Rep 6 (2001) 343-349